Literature DB >> 8366177

Pharmacokinetics of azathioprine after repeated oral and single intravenous administration.

A el-Yazigi1, F A Wahab.   

Abstract

The pharmacokinetics of azathioprine (AZN) were examined in 28 renal transplant patients treated orally with 25 to 150 mg AZN once daily in combination with cyclosporin A and prednisone, and after single intravenous (IV) injection of 5 mg/kg AZN using the rabbit as an in vivo model. The steady-state concentrations of AZN observed in these patients ranged from 6 to 583 micrograms/L, and the interday coefficients of variation of the concentration in three randomly selected patients were 38%, 12%, and 4.6%. The frequency distribution pattern of the apparent oral clearance (TCLor) of AZN separates the patients almost equally into poor (TCLor = 0.126 to 4 L/hour.kg) and extensive metabolizers (TCLor = 5 to 12 L/hour.kg). The data obtained from the IV administration displayed the two-compartment model characteristics with mean (standard error of the mean) of alpha, beta, Vc, and total body clearance of 15.3 (2)/hour, 2.38 (.64)/hour, 1.05 (.3) L/kg, and 8.12 (1.26) L/hour.kg, respectively. The large variability in the pharmacokinetic parameters of AZN in patients and even in rabbits under carefully controlled conditions that may be ascribed to the complexity of its metabolism necessitates a careful approach to its dose selection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8366177     DOI: 10.1002/j.1552-4604.1993.tb04698.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

Review 1.  Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.

Authors:  María del Mar Fernández De Gatta; Dolores Santos-Buelga; Alfonso Domínguez-Gil; María José García
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine.

Authors:  J M Gervasio; R O Brown; J Lima; M G Tabbaa; T Abell; R Werkman; L J Haberer; L J Hak
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

Review 3.  Peripheral Ulcerative Keratitis: A Review.

Authors:  Kiana Hassanpour; Reem H ElSheikh; Amir Arabi; Charles R Frank; Abdelrahman M Elhusseiny; Taher K Eleiwa; Shiva Arami; Ali R Djalilian; Ahmad Kheirkhah
Journal:  J Ophthalmic Vis Res       Date:  2022-04-29

Review 4.  Clinically important drug interactions with disease-modifying antirheumatic drugs.

Authors:  C J Haagsma
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 4.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.